SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ |
|
FORM 8-K |
CURRENT REPORT
|
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
________________ |
|
Date of Report (Date of earliest event reported): July 31, 2007
|
Alpharma Inc.
|
|
(Exact name of registrant as specified in its charter) |
|
Delaware (State or other jurisdiction of incorporation) | 1-8593 (Commission File Number) | 22-2095212 (IRS Employer Identification) |
|
440 Route 22, Bridgewater, New Jersey 08807 (Address of principal executive offices) (Zip Code) |
|
Registrant's telephone number, including area code (866) 322-2525 |
|
|
Not Applicable |
(Former name or former address, if changed since |
last report) |
Item 2.02. Results of Operations and Financial Condition
On July 31, 2007, Alpharma Inc. issued a press release announcing its financial results for the quarter ended June 30, 2007. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statement and Exhibits
(c) Exhibits.
- Press release issued by Alpharma Inc. on July 31, 2007.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALPHARMA INC.
|
| By:/s/ Thomas J. Spellman III |
| Thomas J. Spellman III Executive Vice President, Chief Legal Officer & Corporate Secretary
|
Date: August 1, 2007